IMNM (Immunome, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by IMNM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-27 | Max Rosett | Chief Financial Officer | A | — | — |
| 2026-07-27 | Philip Tsai | Chief Technical Officer | A | — | — |
| 2026-07-27 | Sandra G. Stoneman | CHIEF LEGAL OFFICER & GC | A | — | — |
| 2026-07-27 | CLAY B SIEGALL | President and CEO | A | — | — |
| 2026-07-27 | Kinney Horn | CHIEF BUSINESS OFFICER | A | — | — |
| 2026-07-27 | Robert Lechleider | Chief Medical Officer | A | — | — |
| 2026-07-27 | Jack Higgins | Chief Scientific Officer | A | — | — |
| 2026-07-09 | Kinney Horn | CHIEF BUSINESS OFFICER | MIXED | — | — |
| 2026-07-07 | Robert Lechleider | Chief Medical Officer | MIXED | — | — |
| 2026-07-07 | Isaac Barchas | Director | Sell | — | — |
| 2026-07-02 | Isaac Barchas | Director | Sell | — | — |
| 2026-06-29 | Robert Lechleider | Chief Medical Officer | MIXED | — | — |
| 2026-06-17 | Max Rosett | Chief Financial Officer | MIXED | — | — |
| 2026-06-12 | SANDRA M SWAIN | Director | A | — | — |
| 2026-06-12 | Isaac Barchas | Director | A | — | — |
| 2026-06-12 | JEAN JACQUES BIENAIME | Director | A | — | — |
| 2026-06-12 | James P Boylan | Director | A | — | — |
| 2026-06-12 | PHILIP WAGENHEIM | Director | A | — | — |
| 2026-06-12 | CAROL SCHAFER | Director | A | — | — |
| 2026-06-09 | JEAN JACQUES BIENAIME | Director | MIXED | — | — |
| 2026-05-19 | JEAN JACQUES BIENAIME | Director | Buy | — | — |
| 2026-04-03 | Jack Higgins | Chief Scientific Officer | Sell | — | — |
| 2026-04-03 | Max Rosett | Chief Financial Officer | MIXED | — | — |
| 2026-04-01 | Jack Higgins | Chief Scientific Officer | G | — | — |
| 2026-03-23 | PHILIP WAGENHEIM | Director | Sell | — | — |
| 2026-03-12 | JEAN JACQUES BIENAIME | Director | Buy | — | — |
| 2025-12-30 | CLAY B SIEGALL | President and CEO | Buy | — | — |
| 2025-12-23 | Isaac Barchas | Director | Sell | — | — |
| 2025-12-22 | Philip Tsai | Chief Technical Officer | Buy | — | — |
| 2025-12-22 | CLAY B SIEGALL | President and CEO | MIXED | — | — |
| 2025-12-22 | Jack Higgins | Chief Scientific Officer | G | — | — |
| 2025-12-18 | CLAY B SIEGALL | President and CEO | Buy | — | — |
| 2025-09-11 | Jack Higgins | Chief Scientific Officer | M | — | — |
| 2025-07-31 | CLAY B SIEGALL | President and CEO | A | — | — |
| 2025-07-31 | Sandra G. Stoneman | CHIEF LEGAL OFFICER & GC | A | — | — |
| 2025-07-31 | Max Rosett | Chief Financial Officer | A | — | — |
| 2025-07-31 | Robert Lechleider | Chief Medical Officer | A | — | — |
| 2025-07-31 | Philip Tsai | Chief Technical Officer | A | — | — |
| 2025-07-31 | Kinney Horn | CHIEF BUSINESS OFFICER | A | — | — |
| 2025-07-31 | Jack Higgins | Chief Scientific Officer | A | — | — |
| 2025-06-12 | JEAN JACQUES BIENAIME | Director | A | — | — |
| 2025-06-12 | CAROL SCHAFER | Director | A | — | — |
| 2025-06-12 | Isaac Barchas | Director | A | — | — |
| 2025-06-12 | James P Boylan | Director | A | — | — |
| 2025-06-12 | SANDRA M SWAIN | Director | A | — | — |
| 2025-06-12 | PHILIP WAGENHEIM | Director | A | — | — |
| 2025-06-03 | JEAN JACQUES BIENAIME | Director | Buy | — | — |
| 2025-03-28 | Jack Higgins | Chief Scientific Officer | M | — | — |
| 2025-03-26 | CLAY B SIEGALL | President and CEO | Buy | — | — |
| 2025-03-26 | JEAN JACQUES BIENAIME | Director | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 1,279,914 | — |
| — | 10%+ Owner | 920,939 | — |
| — | President and CEO | 870,704 | — |
| — | Director | 341,147 | — |
| — | Director | 228,669 | — |
| — | Chief Financial Officer | 101,287 | — |
| — | Chief Technical Officer | 81,550 | — |
| — | Chief Medical Officer | 69,805 | — |
| — | Director | 66,953 | — |
| — | Chief Scientific Officer | 61,250 | — |
| — | Director | 60,840 | — |
| — | Director | 51,315 | — |
| — | CHIEF LEGAL OFFICER & GC | 43,805 | — |
| — | Chief Strategy Officer | 42,300 | — |
| — | Director | 40,747 | — |
| — | Director | 38,915 | — |
| — | CHIEF BUSINESS OFFICER | 31,250 | — |
| — | President and CEO | 10,500 | — |
| — | Director | 2,343 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IMNM quote page; the site-wide leaderboard is on the insider transactions hub.